Regeneron Pharmaceuticals' Other Non Operating Income rose 130.92% to $755.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 41.55%. This contributed to the annual value of $844.4 million for FY2024, which is 274.96% up from last year.
According to the latest figures from FY2024, Regeneron Pharmaceuticals' Other Non Operating Income is $844.4 million, which was up 274.96% from $225.2 million recorded in FY2023.
Regeneron Pharmaceuticals' Other Non Operating Income's 5-year high stood at $844.4 million during FY2024, with a 5-year trough of $179.3 million in FY2022.
Moreover, its 3-year median value for Other Non Operating Income was $225.2 million (2023), whereas its average is $416.3 million.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Other Non Operating Income plummeted by 58.90% in 2022, and later soared by 274.96% in 2024.
Over the past 5 years, Regeneron Pharmaceuticals' Other Non Operating Income (Yearly) stood at $290.7 million in 2020, then surged by 50.09% to $436.3 million in 2021, then slumped by 58.90% to $179.3 million in 2022, then climbed by 25.60% to $225.2 million in 2023, then soared by 274.96% to $844.4 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value